Table 3 SNPs with detected significant differences in clinical index.
From: Association of Polymorphisms in Pharmacogenetic Candidate Genes with Propofol Susceptibility
Genotype/alleles | Patients n (frequency) | Cep | MAP (%) | HR (%) | BIS | Time | Total |
|---|---|---|---|---|---|---|---|
5HT2A rs6313 | |||||||
 AA | 46(0.31) | 1.85 ± 0.96 | −11.36 ± 7.13 | −9.92 ± 7.79 | 58.96 ± 10.43 | 187.20 ± 160.80 | 100.02 ± 35.86 |
 GG + GA | 100(0.69) | 1.53 ± 0.76* | −11.09 ± 7.24 | −10.40 ± 7.12 | 60.69 ± 12.28 | 132.00 ± 91.80* | 86.51 ± 22.99 |
GABAA2 rs11503014 | |||||||
 CC | 116(0.83) | 1.65 ± 0.81 | −11.51 ± 6.79 | −9.44 ± 6.94 | 59.84 ± 11.77 | 149.31 ± 115.68 | 91.51 ± 28.26 |
 CG | 23(0.17) | 1.71 ± 1.01 | −10.54 ± 9.70 | −12.85 ± 8.54* | 62.30 ± 10.81 | 171.05 ± 155.89 | 92.61 ± 33.35 |
SCN9A rs6746030 | |||||||
 GG | 120(0.88) | 1.71 ± 0.87 | −11.50 ± 7.73 | −10.02 ± 7.41 | 61.30 ± 10.39 | 160.01 ± 129.09 | 93.33 ± 30.07 |
 AA + GA | 16(0.12) | 1.36 ± 0.59 | −10.79 ± 4.06 | −9.61 ± 6.85 | 51.13 ± 15.37* | 112.95 ± 58.64 | 81.19 ± 20.38 |
GABAA1 rs2279020 | |||||||
 GG | 40(0.29) | 1.51 ± 0.85 | −9.44 ± 5.28 | −9.94 ± 6.51 | 57.15 ± 13.29 | 139.30 ± 122.11 | 88.70 ± 27.32 |
 AA + AG | 98(0.71) | 1.75 ± 0.84 | −12.16 ± 7.92* | −10.01 ± 7.68 | 61.43 ± 10.51* | 160.75 ± 123.68 | 92.97 ± 29.87 |
CHRM2 rs2283265 | |||||||
 CC | 47(0.35) | 1.72 ± 0.88 | −11.23 ± 6.87 | −8.25 ± 7.15 | 60.92 ± 14.62 | 154.80 ± 107.56 | 93.89 ± 33.80 |
 AA + CA | 89(0.65) | 1.66 ± 0.84 | −11.42 ± 7.65 | −10.86 ± 7.32* | 59.94 ± 10.25 | 154.26 ± 129.55 | 90.84 ± 27.47 |
